CA2382655A1 - Antibodies as a cancer diagnostic - Google Patents

Antibodies as a cancer diagnostic Download PDF

Info

Publication number
CA2382655A1
CA2382655A1 CA002382655A CA2382655A CA2382655A1 CA 2382655 A1 CA2382655 A1 CA 2382655A1 CA 002382655 A CA002382655 A CA 002382655A CA 2382655 A CA2382655 A CA 2382655A CA 2382655 A1 CA2382655 A1 CA 2382655A1
Authority
CA
Canada
Prior art keywords
epha2
cells
antibody
cell population
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382655A
Other languages
English (en)
French (fr)
Inventor
Michael Scott Kinch
Nicole Dodge Zantek
Katherine E. Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2382655A1 publication Critical patent/CA2382655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002382655A 1999-08-17 2000-08-17 Antibodies as a cancer diagnostic Abandoned CA2382655A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
US60/149,259 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Publications (1)

Publication Number Publication Date
CA2382655A1 true CA2382655A1 (en) 2001-02-22

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382655A Abandoned CA2382655A1 (en) 1999-08-17 2000-08-17 Antibodies as a cancer diagnostic

Country Status (8)

Country Link
EP (2) EP2312316A1 (enExample)
JP (3) JP4948728B2 (enExample)
AT (1) ATE483978T1 (enExample)
AU (1) AU785445C (enExample)
CA (1) CA2382655A1 (enExample)
DE (1) DE60045075D1 (enExample)
ES (1) ES2357296T3 (enExample)
WO (1) WO2001012840A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1453530A2 (en) * 2001-11-09 2004-09-08 Neuronova AB Method of proliferation in neurogenic regions
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
CA2542631A1 (en) * 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
ATE483978T1 (de) 2010-10-15
EP2312316A1 (en) 2011-04-20
EP1210603A2 (en) 2002-06-05
JP2007291140A (ja) 2007-11-08
AU785445C (en) 2008-01-31
ES2357296T3 (es) 2011-04-25
WO2001012840B1 (en) 2001-09-27
AU785445B2 (en) 2007-06-14
AU6784300A (en) 2001-03-13
JP2003507023A (ja) 2003-02-25
JP4948728B2 (ja) 2012-06-06
DE60045075D1 (de) 2010-11-18
WO2001012840A3 (en) 2001-05-03
JP2012103264A (ja) 2012-05-31
EP1210603B1 (en) 2010-10-06
WO2001012840A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
US20070161064A1 (en) Antibodies as a cancer diagnostic
AU785445C (en) Anti-EphA2 antibodies as a cancer diagnostic
US7090983B1 (en) Methods for detecting early cancer
WO2007124361A2 (en) Soluble b7-h1
EP1930445B1 (en) Kit and method for detection of urothelial cancer
WO2008028066A2 (en) Boris isoforms and methods of detecting and treating disease
US20050214301A1 (en) Antibodies specific for BCR-ABL fusion protein and uses thereof
US20120115151A1 (en) Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53beta
US20060188949A1 (en) Use of protein PLST as a marker for colorectal cancer
AU2011253563A1 (en) Anti-epha2 antibodies as a cancer diagnostic
AU2007202091A1 (en) Anti-epha2 antibodies as a cancer diagnostic
US20130203059A1 (en) Method for Diagnosis of Bladder Cancer and Related Kits
WO2013059105A2 (en) Predictive biomarkers for breast cancer
US8445220B2 (en) Methods of diagnosing latent and active malignancies
Class et al. Patent application title: Method for Diagnosis of Bladder Cancer and Related Kits Inventors: Antonio Feliciello (Parete, IT) Luigi Insabato (Napoli, IT) Assignees: Topogen, Inc.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130729